Comprehensive cost analysis of 4th line + therapies for relapsed/refractory multiple myeloma in Germany: Drug, co-medication, and office-based treatment perspective
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Ulrike Sager, Stefan Norin, Bastian Hatesuer
Institution: Oncopeptides (Sweden)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417004897
Cites:
Cited by:
Related to: